Both of Us Are Wilson Disease Carriers — Can Our Baby Be Tested at Birth?

If you and your partner are both carriers of a Wilson disease mutation, each pregnancy carries a one-in-four chance of producing a child with Wilson disease — a child who has inherited one defective copy of the ATP7B gene from each parent. That probability is real, and your instinct to find out as early as possible is exactly right. The answer to your question is yes: your baby can be tested at birth (or even before birth), and if the result shows Wilson disease, treatment can begin well before any symptoms appear — which dramatically changes the trajectory of the disease.

Understanding Your Situation First

When two people who are each carriers of an autosomal recessive condition have a child together, the odds for each pregnancy are:

• 25% chance the child has Wilson disease (inherits both mutant copies)
• 50% chance the child is a carrier like you (one mutant, one normal copy, no disease)
• 25% chance the child inherits two normal copies (neither carrier nor affected)

This is basic Mendelian genetics, and it applies regardless of how many children you already have or how those children turned out — each pregnancy is an independent event.¹

Wilson disease itself does not typically cause symptoms in infancy. Copper accumulates slowly in the liver, brain, and other organs over years. Symptoms most commonly emerge between the ages of 5 and 35, with liver disease typically appearing earlier than neurological or psychiatric symptoms.² That is both the challenge and the opportunity: there is a long window between birth and symptom onset during which the disease can be identified and treatment started.

Testing at Birth: What’s Available

Genetic testing at birth is the most direct approach. Wilson disease is caused by mutations in the ATP7B gene, and if your specific family mutations have been identified (which they should be if both of you have been genotyped as carriers), a DNA test on your baby can confirm within days whether the child has inherited both mutations, one, or neither.³

Blood for this test can be obtained from: - Cord blood collected at the moment of delivery — the most convenient option, requiring no procedure after birth - Heel-prick blood spot collected in the first 24 to 72 hours (the same sample collected for standard newborn screening) - A standard venous blood draw in the first weeks of life

Testing is typically arranged through a medical genetics laboratory, and you should discuss the plan with your Wilson disease specialist or a genetic counsellor before the birth — ideally during pregnancy — so that everything is in place when the baby arrives.

Standard newborn screening programs do not currently include Wilson disease in the United States, Canada, or most other countries. The disease is rare enough and the currently available blood markers (ceruloplasmin, serum copper) are unreliable in newborns — ceruloplasmin is physiologically low in all newborns regardless of whether they have Wilson disease, making it useless as a newborn screen at this age.⁴ This is why targeted genetic testing, using your known family mutations, is the practical path.

A 2025 advocacy preprint highlights active discussions about adding Wilson disease to newborn screening panels, but as of 2026 this has not been implemented in standard programs.⁵ Molecular (genetic) testing through your specialty care team remains the right route.

Testing Before Birth

If you want to know before the baby is born, two approaches are available:

Prenatal diagnostic testing. Chorionic villus sampling (CVS), performed between 10 and 13 weeks of pregnancy, or amniocentesis, performed between 15 and 20 weeks, can obtain fetal cells for genetic testing. This is an established approach for known autosomal recessive conditions when both parental mutations are identified.⁶ There is a small procedural risk with both tests — discuss this with your obstetrician and maternal-fetal medicine specialist.

Preimplantation genetic testing (PGT-M). If you are considering IVF, embryos can be screened before transfer, and only embryos without Wilson disease can be selected. This approach eliminates the need for prenatal diagnosis during pregnancy but involves the full IVF process. Access and cost vary significantly by country.

Many couples in your situation choose to wait until after birth and do cord blood testing — it is simpler, lower risk, and still early enough to be clinically meaningful.

If the Baby Tests Positive: What Happens Next

A positive genetic test (both mutations present) confirms that the child has Wilson disease but does not tell you how severely they will be affected or when they will show signs. Wilson disease has variable expressivity — some people develop significant liver disease in childhood, others remain asymptomatic into adulthood.³

The standard approach for a presymptomatic diagnosis is:

Regular monitoring from early childhood. The AASLD 2022 Practice Guidance recommends that affected individuals who are identified before symptoms develop be monitored with periodic liver function tests, serum copper, ceruloplasmin, and 24-hour urine copper, with the frequency increasing as the child grows older.² This monitoring detects the earliest signs of copper accumulation before organ damage occurs.

Starting treatment before symptoms appear. There is strong evidence that treating Wilson disease before symptoms develop leads to better long-term outcomes than waiting for symptoms and then treating.⁷ The drug most commonly used in presymptomatic children is zinc, which blocks copper absorption in the gut and has a favourable safety profile that is appropriate for long-term use in children. Chelating agents (penicillamine, trientine) may be used if monitoring shows significant copper accumulation beginning.

Dietary precautions. Even before medication is started, a low-copper diet — avoiding organ meats, shellfish, and other high-copper foods — is a sensible adjunct. See the post on diet and copper for practical guidance.

The Power of Early Diagnosis

The landmark importance of presymptomatic detection was established in the 1980s and has been confirmed repeatedly since: people identified and treated before symptoms appear can often avoid the neurological damage, psychiatric crises, and liver disease that characterised the historical experience of Wilson disease.⁷ A sibling of a known patient who is identified early and treated appropriately can expect essentially normal health and lifespan.¹³

A recent case report of siblings in a family with Wilson disease illustrates this well: the affected sibling identified incidentally through family screening — before any symptoms — had a substantially better outcome than the sibling who had already developed liver disease at diagnosis.⁸

Your proactive approach — thinking about this before your baby is born — puts you in the best possible position to give your child that advantage.

Practical Steps to Take Now

1. Confirm that both your specific ATP7B mutations are on record with a genetics laboratory — this is the information needed to test your baby. If either of you was identified only as a “carrier” without specific mutation documentation, ask your genetics team to retrieve or repeat the mutation analysis.

2. Talk to your Wilson disease specialist during pregnancy about arranging cord blood collection at delivery. Get a written plan in your prenatal record so the obstetric team knows what to do.

3. Ask for a referral to a paediatric hepatologist who has Wilson disease experience. Even if the test comes back negative, a baby where both parents are known carriers deserves a specialist who can set up appropriate follow-up if needed.

4. Connect with family screening resources — this post covers the broader context of screening relatives, which is highly relevant to your situation.

If the test comes back negative — meaning the child has either one copy (carrier) or no copies — that is genuinely good news. A carrier child needs no treatment and will live a normal life. Your follow-up at that point is less intensive, though it is worth discussing with your specialist at what age (typically adolescence or early adulthood) the carrier child might want to learn more about their own carrier status for future family planning.

This post is for educational purposes only. Your specific testing options, timing, and monitoring plan should be designed by your Wilson disease specialist and, ideally, a clinical geneticist or genetic counsellor who knows your family’s specific mutations.

References